Sandoz Australia & New Zealand

Sandoz Australia & New Zealand is an affiliate of Sandoz AG (SIX: SDZ; OTCQX: SDZNY), the global leader in generic and biosimilar medicines with a growth strategy driven by its Purpose: pioneering access for patients. More than 20,000 people of 100 nationalities work together to ensure more than 900 million patient treatments are provided by Sandoz, generating substantial global healthcare savings and an even larger social impact. Its leading portfolio of approximately 1,300 products addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886. Its history of breakthroughs includes Calcium Sandoz in 1929, the world’s first oral penicillin in 1951, and the world’s first biosimilar in 2006. In 2024, Sandoz recorded net sales of USD 10.4 billion.

Privacy Notice: Information shared on this page may be processed by Sandoz to respond to enquiries, administer the community, meet regulatory obligations including adverse event reporting, and improve our communications. Please do not post sensitive personal or health information. For information about how Sandoz handles personal information, please refer to the Sandoz Privacy Notice available at www.sandoz.com/australia-website-privacy-notice/